Zacks Investment Research downgraded Zoetis Inc (NYSE:ZTS) to Sell in a report released today.
- Updated: October 13, 2016
Zacks Investment Research has downgraded Zoetis Inc (NYSE:ZTS) to Sell in a report released on 10/13/2016.
Yesterday Zoetis Inc (NYSE:ZTS) traded -1.15% lower at $50.73. The company’s 50-day moving average is $51.25 and its 200-day moving average is $48.94. The last stock close price is up 3.86% from the 200-day moving average, compared to the S&P 500 which has decreased -0.01% over the same time. 1,336,607 shares of the stock were exchanged, down from an average trading volume of 3,362,750
See Chart Below
Zoetis Inc has a 52 week low of $38.26 and a 52 week high of $53.14 with a P/E ratio of 39.59 The company’s market cap is currently $0.
In addition to Zacks Investment Research reporting its target price, a total of 10 firms have issued a report on the stock. The consensus target price is $52.70 with 0 firms rating the stock a strong buy, 0 firms rating the stock a buy, 0 firms rating the stock a hold, 0 firms rating the stock a underperform, and finally 0 firms rating the stock a sell.
About Zoetis Inc (NYSE:ZTS)
Zoetis Inc. is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The Company has a diversified business, marketing products across over eight core species: cattle, swine, poultry, sheep and fish (collectively, livestock), and dogs, cats and horses (collectively, companion animals), and within over five product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceuticals. It operates through two segments: the United States and International. Within each of these segments, it offers a diversified product portfolio for both livestock and companion animal customers. In addition, its Client Supply Services (CSS) organization provides contract manufacturing services to third parties. It also offers other product categories, such as nutritionals and agribusiness.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.